Success Metrics

Completion Rate
0%(0/3)
Active Trials
2(40%)
Terminated
3(60%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Terminated(3)

Detailed Status

Terminated3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

terminated360%
active_not_recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_2

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621
active_not_recruitingphase_1

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

NCT03333343
terminatedphase_1

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

NCT04294160
terminatedphase_1

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

NCT02974725
terminatedphase_1

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

NCT02607813

Clinical Trials (5)

Showing 5 of 5 trials
NCT04417621Phase 2

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Active Not Recruiting
NCT03333343Phase 1

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Active Not Recruiting
NCT04294160Phase 1

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Terminated
NCT02974725Phase 1

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Terminated
NCT02607813Phase 1

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5